
    
      Chidamideï¼Œa novel histone deacetylase inhibitor has been approved for the treatment of
      relapsed or refractory peripheral T-cell lymphoma in China. The aim of this study was to
      observe the efficacy and safety of Chidamide With Cyclophosphamide, Doxorubicin, Vincristine,
      Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients.
    
  